Combination of cinacalcet, calcitriol, and lanthanum carbonate in treatment of secondary hyperparathyroidism in uremia under hemodialysis
Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 9
Abstract
Objective To observe the efficacy of combined treatment with cinacalcet, calcitriol, and lanthanum carbonate in uremia patients undergoing hemodialysis (HD) with secondary hyperparathyroidism (SHPT). Methods From January 2020 to December 2022, 80 uremia patients under HD with SHPT treated at Huangshan City People's Hospital were selected. They were randomly divided into the control group (40 cases, treated with calcitriol) and the study group (40 cases, treated with a combination of cinacalcet, calcitriol, and lanthanum carbonate). The calcium-phosphorus product, intact parathyroid hormone (iPTH), parathyroid volume, and carotid intima-media thickness (IMT), as well as adverse reactions, were compared between the two groups. Results Compared with before treatment, both groups showed a decrease in calcium-phosphorus product and iPTH after 1, 3, and 6 months of treatment (P＜0.05). Moreover, compared with the control group, the study group had lower calcium-phosphorus product and iPTH after 1, 3, and 6 months of treatment (P＜0.05). Compared with before treatment, both groups showed a reduction in parathyroid volume after 1, 3, and 6 months of treatment (P＜0.05). The study group also showed a reduction in carotid IMT after 3 and 6 months of treatment (P＜0.05), while the control group showed a reduction in IMT after 6 months of treatment (P＜0.05). Furthermore, compared with the control group, the study group had lower parathyroid volume and IMT after 3 and 6 months of treatment (P＜0.05). The incidence of adverse reactions in the study group was 17.50%, which was not significantly different from the 15.00% in the control group (χ2=0.092, P=0.762). Conclusion For uremia patients under HD accompanied by SHPT, combined treatment of cinacalcet, calcitriol, and lanthanum carbonate can improve calcium and phosphorus metabolism, regulate iPTH, reduce parathyroid volume and the risk of carotid atherosclerosis, without increasing adverse reactions.
Authors and Affiliations
WANG Chengjun , WANG Hong, WAN Jiakui, SHAO Jue
Keywords
Related Articles
- EP ID EP745465
- DOI 10.13429/j.cnki.cjcr.2024.09.018
- Views 41
- Downloads 0
Decision tree analysis of mental resilience trajectory and core influencing factors in patients with traumatic fracture
Objective To investigate the trajectory of mental resilience in patients with traumatic fracture and analyzethe predictive factors of different trajectory subtypes, so as to provide a reference for intervention. Methods...
Timing of blood purification therapy in acute pancreatitis with systemic inflammatory response syndrome
"<b>Objective</b> To explore the timing of blood purification (BP) therapy in patients with acute pancreatitis (AP) who develop systemic inflammatory response syndrome (SIRS). <b>Methods</b> A retrospective collection...
Research advances on the association of nicotinic acetylcholine receptor-related genes and their polymorphisms with lung cancer
Pulmonary embolism and deep venous thrombosis are collectively referred to as venous thromboembolism, while pulmonary embolism is generally caused by deep venous thrombosis, which has the characteristics of sudden and mo...
Treatment progress in remission of type 2 diabetes
Type 2 diabetes is a reversible disease. The remission of type 2 diabetes is defined as maintaining a glycosylated hemoglobin (HbA1c) level＜6.5% and fasting plasma glucose＜7.0 mmol/L for at least 3 months after discont...
Efficacy and safety of filiform needle combined with modified Zilan decoction for treatment of verruca plana among adolescents
Objective To evaluate the clinical efficacy and safety of filiform needles combined with modified Zilan decoction in treating verruca plana in adolescents. Methods A total of 120 adolescents with verruca plana treated at...